Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, non-randomized, open-label safety study of BLP25 liposome vaccine (L-BLP25) [cancer vaccine BLP25; Stimuvax] in non-small cell lung cancer (NSCLC) patients with unresectable stage III disease

Trial Profile

A multi-center, non-randomized, open-label safety study of BLP25 liposome vaccine (L-BLP25) [cancer vaccine BLP25; Stimuvax] in non-small cell lung cancer (NSCLC) patients with unresectable stage III disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs Tecemotide (Primary) ; Cyclophosphamide
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Merck KGaA
  • Most Recent Events

    • 08 Aug 2012 Actual end date (1 Sep 2009) added as reported by ClinicalTrials.gov.
    • 02 Jun 2008 Two-year survival data presented at ASCO 2008.
    • 28 May 2008 The expected completion date for this trial is now 1 Jun 2008, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top